Seventeen years’ experience with Autoplex ® /Autoplex ® T: evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia centre[Note 2. Autoplex® T and Autoplex® are registered trademarks of Nabi, ...]

A retrospective case analysis of the use of Autoplex T ® (anti‐inhibitor coagulant complex [heat treated]) at a major haemophilia treatment centre is described. Twenty‐three haemophilia A patients with a history of high‐titre (>10 BU), high‐response inhibitors were treated for a total of 54 bleeding episodes requiring hospital admission and/or surgical intervention. Effective or partially effective haemostatic control was achieved within 72 h in 94% of reported cases (effective 85%; partially effective 9%). The incidence of adverse reactions was low and there were no thrombotic complications. In bleeding episodes for which BU titres were determined within 6 months pre‐ and 6 months post‐treatment, there was little tendency for Autoplex T to cause an anamnestic response (1 of 19 bleeding episodes). In the three invasive surgical procedures included in the case review, coverage with Autoplex T resulted in no postoperative complications, no bleeding at the surgical site, and no postoperative haematoma. The results support the efficacy and safety of Autoplex T in the treatment of bleeding episodes and haemostatic coverage of surgical procedures in haemophilia A patients with inhibitors.